Safyral Birth Control
The US Food and Drug Administration (FDA) has issued a warning about Safyral birth control and other contraceptives that contain drospirenone, following concerns about drospirenone side effects. According to a document issued by the FDA, the risk of serious Safyral side effects, including a reported increased risk of blood clots will now result in strengthened warnings on the Safyral label.
FREE SAFYRAL LAWSUIT EVALUATION
GET LEGAL HELP NOW
"All birth control pills pose a risk of blood clots," the FDA stated (09/26/11). "Several epidemiological studies have reported that the risk of blood clots for women who use birth control pills containing drospirenone is higher than that for women who use birth control pills containing the progestin levonorgestrel. Other studies have not reported an increase in risk."
Safyral Side Effects
Blood clots can cause serious injury, especially if they break loose from the patient's vein and move to the patient's lung, where they can cause a potentially fatal pulmonary embolism. According to the FDA, two recently published studies found an increased risk for blood clots in women taking drospirenone-containing pills compared with women taking levonorgestrel-containing pills.
According to a study published in the British Medical Journal (04/21/11), women who use birth control that contains drospirenone have approximately three times the risk of developing a non-fatal idiopathic venous thromboembolism as women who use contraceptives that contain levonorgestrel.
"This study adds to the emerging evidence that use of the oral contraceptive containing drospirenone is associated with a higher risk of venous thromboemolism than are preparations containing levonorgestrel," researchers wrote. Furthermore, researchers said there is no clear evidence that drospirenone pills have increased benefits compared with contraceptives that contain levonorgestrel, making drospirenone a less than ideal first line contraceptive.
Meanwhile, a second study published in the British Medical Journal (04/21/11) found that woman who used birth control that contained drospirenone had approximately double the risk of non-fatal venous thromboembolism as women who used a birth control that contained levonorgestrel.
Drospirenone Birth Control Pills
Drospirenone is a type of female hormone called progestin. It has been linked to an increased risk of blood clots in some studies. Safyral was approved by the FDA on December 17, 2010, as an oral contraceptive. The drug includes drospirenone and folate, similar to Beyaz, but in different amounts. Safyral is manufactured by Bayer HealthCare Pharmaceuticals, Inc.
Lawsuits have been filed against drugmakers who manufacture birth control with drospirenone as an active ingredient. Allegations have been raised in some court documents that Bayer did not notify the FDA of all cases of blood clots linked to drospirenone-containing birth control before the drugs were approved for use.
Safyral Birth Control Legal HelpIf you or a loved one has suffered damages from Safyral Birth Control, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on
SAFYRAL LEGAL ARTICLES AND INTERVIEWS
Despite Safyral and Drospirenone Concerns, It’s Business As Usual at Bayer
Safyral: Is There a Link between Drospirenone and Strokes?